Prajoko Yan Wisnu, Aryandono Teguh
Department of Surgery, Faculty of Medicine, Diponegoro University, Tembalang Semarang, Indonesia E-mail :
Asian Pac J Cancer Prev. 2014;15(2):595-8. doi: 10.7314/apjcp.2014.15.2.595.
NF-κB inhibits apoptosis through induction of antiapoptotic proteins and suppression of proapoptotic genes. Various chemotherapy agents induce NF-κB translocation and target gene activation. We conducted the present study to assess the predictive value of NF-κB regarding pathologic responses after receiving neoadjuvant chemotherapy.
We enrolled 131 patients with locally advanced invasive ductal breast carcinoma. Immunohistochemistry (IHC) was used to detect NF-κB expression. Evaluation of pathologic response was elaborated with the Ribero classification.
Expression of NF-κB was significantly associated with poor pathological response (p=0.02). From the multivariate analysis, it was found that the positive expression of NF-κB yielded RR=1.74 (95%CI 0.77 to 3.94).
NF-κB can be used as a predictor of poor pathological response after neoadjuvant chemotherapy.
核因子κB（NF-κB）通过诱导抗凋亡蛋白和抑制促凋亡基因来抑制细胞凋亡。多种化疗药物可诱导NF-κB易位并激活靶基因。我们开展本研究以评估NF-κB对接受新辅助化疗后病理反应的预测价值。
我们纳入了131例局部晚期浸润性导管癌患者。采用免疫组织化学（IHC）检测NF-κB表达。采用里韦罗分类法详细评估病理反应。
NF-κB表达与病理反应不佳显著相关（p = 0.02）。多因素分析发现，NF-κB阳性表达的相对危险度RR = 1.74（95%可信区间0.77至3.94）。
NF-κB可作为新辅助化疗后病理反应不佳的预测指标。
